Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;239(10):3367-3375.
doi: 10.1007/s00213-022-06230-5. Epub 2022 Sep 5.

A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years

Yu Hong  1 , Wenbo Huang  2 , Daiyin Cao  3 , Jilai Xu  4 , Huifan Wei  5 , Jie Zhang  6 , Li Wang  7
Affiliations

A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years

Yu Hong et al. Psychopharmacology (Berl). 2022 Oct.

Abstract

Rationale: Mania (or manic episodes) is a common symptom of bipolar disorder and is frequently accompanied by hyperactivity and delusions; given the cost and resources available, there is a paucity of evidence for direct comparison of different drugs.

Objectives: We aimed to provide evidence-based recommendations on the efficacy of overall currently used pharmacological treatments for patients with acute bipolar mania.

Method: We conducted a systematic review and network meta-analysis (NMA) using a Bayesian network frame. We searched the primary literature databases without language restrictions until Dec 18, 2021, for reports of randomized controlled trials (RCTs) of suspected antimanic drugs used as monotherapy for patients with acute bipolar mania, with the primary outcomes being efficacy (mean difference (MD), standardized mean difference (SMD) in the change of mania score).

Results: Eighty-seven studies were included in which 18,724 manic participants (mean age = 34.6 years, with 50.36% males) were allocated at random to one of 25 active medication drug therapies or placebo, resulting in 87 direct comparisons on 192 data points. Tamoxifen (- 22·00 [- 26·00 to - 18·00]) had the best efficacy over the placebo. Meanwhile, risperidone (- 6·60 [- 8·40 to - 4·90]) was substantially more effective than placebo in treating acute mania. Carbamazepine, haloperidol, ziprasidone, cariprazine, olanzapine, quetiapine, aripiprazole, lithium, paliperidone, asenapine, and divalproex were noticeably more effective than placebo.

Conclusions: Overall, tamoxifen appears to be the most effective of the currently known pharmaceutical therapy available to treat acute mania or manic episodes; however, this conclusion is restricted by the scale of RCTs conducted, and risperidone was found to be the most effective medication among antipsychotics. Carbamazepine, haloperidol, ziprasidone, cariprazine, olanzapine, quetiapine, aripiprazole, lithium, paliperidone, asenapine, and divalproex were noticeably effective in treating acute mania or manic episodes.

Keywords: Efficacy; Mania; Network meta-analysis; Pharmacological interventions.

PubMed Disclaimer

References

    1. Amrollahi Z et al (2011) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129(1–3):327–331. https://doi.org/10.1016/j.jad.2010.08.015 - DOI - PubMed
    1. Baldessarini RJ et al (2019) Pharmacological treatment of adult bipolar disorder. Mol Psychiatry 24(2):198–217. https://doi.org/10.1038/s41380-018-0044-2 - DOI - PubMed
    1. Bebchuk JM et al (2000) A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57(1):95–97. https://doi.org/10.1001/archpsyc.57.1.95 - DOI - PubMed
    1. Caldwell DM et al (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897–900. https://doi.org/10.1136/bmj.331.7521.897 - DOI - PubMed - PMC
    1. Chadwick D (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group Lancet 354(9172):13–19. https://doi.org/10.1016/s0140-6736(98)10531-7 - DOI

Publication types

LinkOut - more resources